A re-examination of the methods of developing new treatments for patients with prostate cancer whose disease has progressed during hormone therapy is necessitated by the following: 1) the impact of prostate-specific antigen (PSA) testing on patient selection, 2) the increasing number of studies using noncytotoxic approaches, and 3) the lack of validated methods to report outcomes. PSA monitoring after primary therapy has increased the number of patients referred for therapy with a rising value in this marker or an asymptomatic change in a radionuclide bone scan as the only manifestation(s) of relapse. The development of drugs for this population of patients presents a unique challenge because the classical criterion used to assess efficacy in the phase II setting, i.e., the presence of objective changes in measurable disease sites, frequently does not apply. Since no approach has been proven to prolong survival, the highest priority must be placed on developing new therapies. Standardizing the methods for evaluating treatments is also essential so that promising strategies are pursued and inactive therapies are not developed
A close inspection of clinical trials involving patients with prostate cancer whose disease has progressed during hormone therapy reveals a profound heterogeneity that limits the interpretation of results. The causes include methodologic, patient, and tumor factors. Inconsistencies in the definition of "relapse" as well as in the criteria for patient enrollment are also contributory. The disease itself is not one illness, but a spectrum of diseases, as demonstrated by patients who present with a rising serum prostate-specific antigen (PSA) value as the only sign of tumor growth, those with disease progression in bone with or without soft-tissue masses, and those with soft-tissue lesions and no bone disease. Patients with prostate cancer also include a distinct subset with rapidly advancing disease in the pelvis or in a viscera] site, disproportionately low PSA levels relative to tumor burden, and, if present, lytic as opposed to blastic bone lesions. Are these tumors biologically similar? No. Will their sensitivity to a given treatment be the same? Not likely. As prostate cancers grow from a subclinical (rising PSA value) to a clinically detectable (imaging study revealing abnormality or presence of a palpable mass) stage, there is an increasing probability of mutations that may alter the sensitivity to treatment (1-3). An example is the increase in the frequency of mutations in the p53 gene (also known as TP53) detected in tumor specimens ranging from the hormone-naive (i.e., hormone-untreated) primary to the hormone-naive metastatic to the androgen-independent metastatic states (4) (5) (6) .
Adding to the confusion are reports that suggest that upwards of 40%-50% of patients who have had disease progression while on hormone therapy "respond" if post-therapy changes in PSA value are considered as the primary end point of a trial. But despite the increasing number of trials using this outcome measure, there are no standard methods of reporting outcomes; more importantly, none of the "criteria" have been validated in the phase III setting using the definitive end point of survival. A clinical experiment requires the generation of a specific hypothesis, definition of the patients who are eligible for enrollment, the actual treatment, and the end point(s) ( Table  1) . These methods must be standardized, particularly as we begin to translate promising laboratory studies in the areas of tumor differentiation, apoptosis, metastasis, and angiogenesis to the clinic.
I. Defining the Question
Interpreting outcomes is difficult if the specific hypothesis is not defined clearly. Several hypotheses are listed in Table 2 . Each requires a unique design and unique measurements. One hypothesis is whether drug a causes the regression of bidimensionally measurable tumor masses secondary to prostatic cancer. The results would be useful to a physician treating a patient with measurable disease, but they may not be applicable to the patient with osseous disease. A second hypothesis is whether III. End points for phase II investigations IV. Developmental sequence:
Step I:
Step II:
A A. Define appropriate population based on presumed mechanism(s) of the study agent(s). B. Define primary end point based on A. C. Trials in which primary end point is satisfied are developed further.
Randomized comparisons
Response Time to disease progression Survival drug b delays the progression of disease. This end point would be appropriate for a drug that inhibits the metastatic process in patients with rising PSA values with negative imaging studies who are at risk for metastatic progression. Retinoids, believed to differentiate tumors, might also delay progression without changes in tumor size. These agents might be best evaluated by use of a pathologic end point in patients with established disease. Another hypothesis is whether drug c has an ameliorating effect on the pain from osseous metastases. For this outcome, pain relief or other measures of quality of life might be more relevant. However, a drug that relieves pain may do so without killing tumor cells, a result frequently seen with bone-seeking radiopharmaceuticals such as 89-strontium (13), 186-rheniumhydroxyethylidene diphosphonate (14) , nonradioactive bisphosphonates (15, 16) , and mitoxantrone (17) . Nevertheless, if this end point is reproducibly quantitated before and after therapy, incorporating parallel declines in analgesic use and other measures of quality of life, a physician evaluating a patient with pain can make a meaningful recommendation on how best to relieve pain.
II. Clinical Trial Eligibility: Measurable Disease Alone Just Won't Do
Before enrollment in a trial, each patient is evaluated, and the extent of disease is assessed through a physical examination that includes a digital rectal examination and imaging studies, such as a radionuclide bone scan, a computed tomography scan, or magnetic resonance imaging. To maximize the chance of response, most trials appropriately require an ambulatory performance status (Karnofsky's performance status of >60 or Eastern Cooperative Oncology Group performance status of 0, 1, or 2); an adequate hematologic, hepatic, and renal reserve; and an adequate life expectancy based on disease extent and medical comorbidities. When the agent under study is a cytotoxic drug, patients who have received prior chemotherapy are typically excluded. Unfortunately, this simple criterion is not a requirement for many trials, and seldom are outcomes separated on the basis of whether a patient has received or responded to a specific chemotherapy.
Demographics
Patient demographics are recorded so that outcomes can be analyzed for specific prognostic factors. Currently, performance status and base-line levels of hemoglobin, alkaline phosphatase, and lactate dehydrogenase are considered prognostic for survival (18) (19) (20) (21) (22) (23) , whereas the data on base-line PSA levels are conflicting (23) (24) (25) (26) . Although these factors have been utilized to determine pretherapy parameters associated with specific outcomes, they have not been utilized prospectively for risk strati- fication in clinical trials. Of greater concern is that the extent of disease at the time hormone therapy was first instituted is rarely considered. In this context, it is unlikely that a patient who has received hormone therapy for a rising PSA value after surgery or radiation therapy has the same prognosis as a patient with the same rise in PSA level who had symptomatic bone metastases at the time hormone therapy was instituted, independent of the treatment used. The resulting stage migration limits our ability to interpret survival data in nonrandomized trials.
Extent of Disease: Measurable Versus Evaluable Lesions
The ability to quantitate tumor regression and progression in a reproducible way is limited in prostate cancer because the predominant pattern of spread is to bone. To circumvent the problem, and before the availability of PSA testing, many investigators restricted entry to clinical trials to patients with bidimensionally measurable tumor masses (27) . At the Memorial Sloan-Kettering Cancer Center, this requirement excludes more than 90% of patients from study.
Once the extent of disease evaluation is completed, each tumor manifestation should be recorded independently. This should include the number of patients with measurable disease, the specific sites of involvement (nodal, prostatic, and/or visceral), the number of patients with disease progression as seen by bone scan, and the number of patients with abnormal marker values. Cancer-related symptoms and the proportion of patients who require narcotics to control pain should also be recorded. Separating disease manifestations in this manner allows a more precise assessment of the effects of a given treatment on prostate cancers that are located at different sites (see below) and result in specific patterns of symptoms.
Hormone Sensitivity: When Are We Treating "HormoneIndependent" or "Hormone-Refractory" Disease? Serum testosterone determinations. There have been distinct changes in the ways that hormone therapies are utilized, which allows the prospective identification of subsets of patients who may respond to androgen deprivation. Included among such patients are those who were initially treated with neoadjuvant androgen deprivation prior to radiation therapy or surgery and whose disease later progressed (28, 29) , those who were treated as part of a formal policy of "intermittent therapy" (30) , and those who have received anti-androgen therapy alone. In all of these situations, the majority of tumors still depend on androgens for growth. For this reason, we recommend documenting that the patient is indeed "castrate" (serum testosterone level <30 ng/mL) prior to trial entry. Those patients who are not castrate are first treated with hormone therapies that lower serum testosterone levels.
It has been recognized for many years that a proportion of patients whose disease has progressed while on one hormone treatment may respond to treatment with a second hormone. In spite of this observation, few trials restrict entry on the basis of the number of, the type of, and/or the response to previous hormone treatment(s) that a patient may have received. As such, the true response proportions to second-line hormone agents such as diethylstilbestrol, megestrol acetate, or ketoconazole are largely unknown for distinct populations of patients who have been treated previously with one or more hormone regimens. The prognostic significance, if any, of pretreatment testosterone levels in the castrate (20-50 ng/mL) range is likewise unknown. These questions can be addressed only in prospective trials that include patients with defined hormone exposures.
Determining which tumors are resistant to hormones has become more important as more patients are referred for secondline therapies with a rising PSA value as the only sign of disease progression. While it is recognized that second-line hormone therapies will not be curative, in most cases they are safer and may produce therapeutic outcomes that compare favorably with those obtained using more toxic approaches. Similarly, because prostate cancers increase proliferation rates in response to androgens, patients who have not been surgically castrated are advised to continue receiving gonadotropin-releasing hormone (GnRH) analogues so that castrate levels of testosterone are maintained. Allowing androgen levels to increase by discontinuing a GnRH analogue may cause the disease to progress, which may be interpreted as a lack of response to a study drug. Although the adverse effect of endogenous testosterone is controversial (31), the administration of exogenous testosterone has been shown to decrease survival in a randomized trial (52) .
Unrecognized "chemohormonal" approaches: influence of concomitant medications and hormonally based combinations on outcomes. The medications used to ameliorate the toxic effects of a chemotherapeutic agent may in themselves have antitumor activity. Examples include the coadministration of dexamethasone to reduce the emetic effect of cisplatin or hypersensitivity reactions to paclitaxel (Taxol) (12) , the use of hydrocortisone to negate the adrenal inhibitory effects of suramin (33) , and the use of ketoconazole in combination with doxorubicin (7) . This factor alone may have contributed to the range of response proportions observed in suramin trials (34) . The situation is similar for estramustine-based combinations. This agent, currently the only drug approved by the Food and Drug Administration for the treatment of relapsed prostate cancer, would be anticipated to produce a minimum response proportion of 20% based on the observed outcomes reported in a contemporary trial (35) .
Steroid hormone withdrawal responses. In 1993, withdrawal responses following the selective discontinuation of flutamide in patients with progressive disease on combined androgen blockade were first reported (36) (37) (38) . The responses were not limited to PSA declines, since in several patients there was objective shrinkage of measurable tumor masses as well as an abatement of cancer-related symptoms such as pain or anemia. Many of the patients who benefited had disease progression while on multiple hormone therapies and chemotherapy (36, 38) , an indication that their physicians had viewed their tumors as "hormone refractory." More recently, it has been recognized that withdrawal responses represent a more generalized phenomenon (39) , since objective benefit has been observed following the discontinuation of a number of agents that act via steroid hormone receptors, such as the anti-androgen bicalutamide (Casodex; Zenaca Pharmaceuticals Group, Wilmington, DE) (40, 41) , megestrol acetate (42), diethylstilbestrol (43) , and retinoids (44) . In clinical practice, with the exception of treatment with bicalutamide, withdrawal responses, when they occur, can be identified rapidly, so that sensitivity can be determined within 4 weeks by checking a PSA level at week 2 and week 4. However, bicalutamide has a long terminal half-life (45) , and withdrawal responses do not occur for up to 8 weeks after discontinuation of this drug (40, 41) . Patients who respond are monitored serially until progression, assessed by rising PSA values or other disease manifestations, is again documented, at which point alternative therapies can be considered.
Androgen independence versus hormone independence. The changes in the use of hormone therapy and the observed responses to second-line hormone therapies alone or as part of chemotherapy regimens, coupled with the clinical benefits observed following steroid hormone withdrawal, have led us to propose a classification scheme based on the hormone sensitivity of the tumor (Table 3 ) (46) . In this scheme, a tumor that is proliferating despite castrate levels of testosterone that respond to additional hormonal maneuvers) is androgen independent and hormone sensitive. A tumor that has not responded to sequential hormonal manipulations is androgen independent and hormone insensitive. It is the latter tumor that is typically classified as hormone refractory (47) .
Definition and Documentation of Disease Progression Prior to Entry
When utilizing radionuclide bone scans, some investigators require "new" lesions, whereas others permit an increase in the intensity of existing lesions as an index of disease progression. The former is preferred. Cancer-related symptoms can be difficult to quantify, and it is well recognized that pain in an osseous site or an increase in urinary symptoms may have a nonmalignant etiology.
Few investigators would disagree that enlargement of a tumor mass constitutes disease progression. However, despite the fact that rising PSA values have been shown to antedate other objective measures of progression for all stages of the disease, there are no standard criteria with respect to the degree of increase in PSA values or the number of times that PSA values must increase before a patient can be considered reliably to have progressive disease. Most clinical trials do not specify the number of PSA levels, the percentage increase, or the interval over which the increase must be documented to enter a patient in a study. Before enrolling a patient with a rising PSA value as the only sign of disease and to minimize the effects of assay variance and spontaneous fluctuations in PSA levels that may occur, we require a minimum of three elevations greater than 50% above the nadir value documented at a minimum of 2 or more weeks apart.
From an operational standpoint, before enrolling an individual in a clinical trial testing a compound in patients with androgen-independent, hormone-insensitive disease, we require disease progression after primary hormone therapy with castrate levels of testosterone, a trial of hormone withdrawal, and one second-line manipulation. Those who respond can be considered for a third hormone, whereas those who do not can be considered for the clinical trial.
III. End Points for Phase II Investigations: Importance of Comparing Apples With Apples and Oranges With Oranges
With currently available treatment methods, a complete response simply does not occur with any regularity. Even if all of the tumor were eliminated with a cytotoxic agent, most of the imaging techniques currently in use would fail to normalize within the time interval when outcomes are typically assessed and the first decision to continue or discontinue therapy is made. For phase II trials, this interval is usually 2-3 months after treatment is initiated. As a result, most responses are classified as partial or stable, which in reality represents a range of outcomes. It was hoped that the addition of serial PSA determinations would improve our ability to monitor disease status. However, it must be recognized that the "criteria" utilizing post-therapy PSA changes are only proposed outcome measures that have not been validated.
A detailed analysis of all chemotherapy trials is beyond the scope of this review and has been reported previously (48) (49) (50) . The difficulties encountered when attempting to recommend one treatment over another are typified by the range in response proportions, 5% (57) to 84% (52), reported with doxorubicin. Part of the difference is related to drug delivery, since few patients in the former trial received a dose rate above 45 mg/m 2 , the dose rate found to be a threshold for response in early phase II trials (55) . Equally important are the response criteria. In a trial of doxorubicin analyzed by different criteria, the response proportion was 33% (52) using the end point of measurable disease regression and 84% (52) if "stable" (54) disease was included. In a trial of mitoxantrone, a response proportion of 16% was observed using post-therapy PSA changes as the outcome measure (55) versus 50% when subjective criteria were utilized (17, 56) . While each outcome measure may be clinically important for the appropriate patient population, too often these distinctions are lost in clinical practice.
Individual Measures

Measurable Disease
When present and monitored serially after treatment, this criterion is probably the most universally accepted method to classify a patient in a complete or partial response category and, when based on imaging studies, the most easily verified and validated by independent reviewers. In most contemporary phase II trials, the number of patients with measurable tumors is generally fewer than 10, which results in wide confidence intervals. This range can be narrowed only by the enrollment of larger numbers of patients with measurable disease in clinical trials.
Aside from the restrictive nature of these trials, the majority of measurable masses are at lymph node sites in the pelvis or retroperitoneum. Less frequently, patients with visceral disease in the setting of low PSA values are enrolled. In the latter situation, a repeat biopsy of the visceral lesion will frequently show histologic evidence of a neuroendocrine phenotype (57, 58) . There is a question as to whether the response of a soft-tissue mass can serve as a surrogate for a response in bone. In one trial, soft-tissue regression was accompanied by osseous progression (59) . This difference in sensitivity in nodal versus osseous sites has also been observed following androgen ablation (60) and may be related to specific growth factors produced in bone stroma, not present in nodal sites, that stimulate cell proliferation and, probably, resistance to treatment (67) .
Osseous Disease
By its nature, proliferation in bone is difficult to quantitate by means of conventional imaging techniques. The situation is complicated by the fact that tumor growth in bone marrow results in an increase in bone formation and osteoblastic changes visible on plain radiographs in more than 90% of cases with abnormal films. In its end stage, the marrow space can become completely replaced by calcified bone. Although most physicians accept that sclerotic healing of a lytic lesion constitutes tumor regression, the sequential monitoring of lesions that are initially sclerotic is problematic because histologic reversion to a normal bone architecture rarely occurs. Even if all tumor cells are destroyed, there may be no radiographic changes visible. In these cases, only a direct biopsy of the area can determine whether or not tumor cells are in fact present. As such, bone radiographs are rarely utilized in the primary assessment of response in phase II trials.
Several groups have proposed staging classifications based on the pattern of distribution of the imaging isotope in the skeleton (21, 25, 62) or on the quantitation of the number of sites (63) . The criteria for response and progression vary widely and are difficult to reproduce on a large scale. There is also inconsistency among investigators with regard to the use of bone scans to assess outcomes. Torti et al. (52) recommended repeating scans at 3-month intervals, but they did not utilize the results to classify a patient in a responding category. However, a patient classified as a partial responder or as having stable disease could not have "evidence of progression on bone scan or bone roentgenograms." Progression was defined as more than three new lesions at 6 months or more than three new lesions at any time of progression of disease-related symptoms. Sella et al. (7) repeated bone scans at 2-month intervals. They judged a scan to have shown "improvement" if there was a reduction in the intensity or the amount of abnormal radionuclide uptake or to have shown "progression" if there was the "appearance of an unequivocal new lesion or increase in the intensity or amount of abnormal [radionuclide] uptake." They considered an increase in the intensity of a lesion in a bone scan as evidence of treatment failure only if it was associated with an increase in PSA value or worsening pain. Kelly et al. (64) required a greater than 50% reduction in bone lesions for a partial response classification and one or more new symptomatic lesions for progression; all other outcomes were classified as stable disease. Other investigators (12) have not included bone scans in their response assessments.
Our current view is that bone scintigraphy is valuable in determining disease extent and may influence the initial decision to recommend a systemic versus localized approach. It may also provide insight about when to conduct additional imaging studies of specific areas, such as magnetic resonance imaging for a suspected epidural lesion, or when to exclude metastatic disease in an area where degenerative joint disease or osteoporotic collapse is frequent. A recent analysis (65) suggested that we are performing bone scans too frequently, such that, as a stand-alone method, it has little impact on clinical decision-making. For example, a patient who has shown no evidence of clinical or biochemical progression is rarely taken off a clinical trial on the basis of the results of a bone scan at 8 weeks alone. Similarly, a patient with a stable scan who develops new pain in a metastatic lesion would be considered to have disease progression independent of the scan results. Thus, only when a patient has shown clinical benefit for 3 months or more can we begin to visualize meaningful changes (65) .
Tumor-Specific Markers
Metastatic prostate cancer can result in changes in a number of biochemical factors that can be monitored in the blood or in the urine. These changes can be classified into those that are tumor specific (e.g., PSA and acid phosphatase), those that reflect tumor burden (e.g., lactate dehydrogenase), and those that reflect the secondary changes of the tumor on the host (e.g., markers of bone formation, such as alkaline phosphatase and osteocalcin, and of bone resorption, such as urinary hydroxy-
Prostate-specific antigen. PSA is a single-chain glycoprotein that has a molecular mass of 33 000 daltons. It is not prostate or prostate cancer specific and has been found in patients with nonmalignant enlargement of the prostate as well as in patients with other cancers, such as those of the breast and the pancreas (66) . In cancer, serum PSA values vary as a function of the number of cells secreting the protein and the amount that is expressed by each cell. There are a number of commercially available assays for PSA. Most of these assays rely on monoclonal or polyclonal antibodies against specific epitopes on the molecule (67, 68) . Unfortunately, the results are not interchangeable, making it important to use measurements from the same laboratory when monitoring a patient on a longitudinal basis.
We initially proposed the use of post-therapy changes in serum PSA as an outcome measure in relapsed disease because 1) rising PSA values antedate clinical progression for all other stages of the disease, 2) more than 90% of patients with progressive disease after hormone therapy have elevations in this parameter, 3) responses in bone are difficult to assess, and 4) use of this measure would permit more agents to be screened in a shorter period of time. In our phase II design, the null hypothesis under study was that agents that do not produce a defined degree of decline in PSA value on multiple determinations for a defined duration (see below) are inactive and do not warrant further investigation (69). It was not our intent to use this parameter as a "surrogate" for response.
The end point of a 50% post-therapy decline was derived from a multivariate analysis of prognostic factors for the survival of patients with hormone-independent disease who were treated with systemic therapies. Of the 20 factors considered, whether or not a patient showed a 50% or greater decline in PSA value following therapy was most significant, with the median survival of patients showing a 50% or greater (23 cases) versus no 50% decline (91 cases) being 21 versus 8 months, respectively (logrank test, P = .0002). The model was subsequently validated using an independent dataset of 91 patients treated in Norway (23) . Although other groups (7, 11, 70) have confirmed the prognostic significance of a 50% or greater decline in PSA value from base line, no other report utilizing a post-therapy decline end point to date has included both a multivariate analysis of known factors and a validation of the results with an independent test-set of patients. A recent report (26) evaluating the prognostic significance of a single post-therapy PSA decline at 4 weeks in patients treated with suramin showed no association between a given degree of decline and outcome. This lack of an association may have been a function of the drug itself or because, to be classified as a "responder," only one determination was required (26) .
Unfortunately, there has been no consistency in the "criteria" proposed and utilized by different investigators. Examples of such criteria are illustrated in Table 4 , which is a summary of contemporary trials using estramustine-based combinations. As shown in Table 4 , some report a 50% decline and others an 80% decline (72) . In one case, the same investigator (9,72) utilized different criteria in different studies. There is also no consistency with regard to the frequency of PSA measurements. Some investigators have used weekly (26, 38) , others biweekly (i.e., every 2 weeks) (64), and others monthly (72) determinations. Even when the same degree of decline is used, the number of measurements that meet the "criteria" may not be the same. Some researchers required three (34) , others one (77), and some simply did not state the number (72) . Again, changing definitions resulted in a "response proportion" ranging from 5% to 45% for the same patient population treated in a phase FI trial (34) . Currently, it is unknown whether a 50% decline would be as stringent as an 80% decline. Intuitively, the greater degree of decline would seem preferable; however, a 50% decline that is prolonged (>1 year) may prove more meaningful than an 80% decline that lasts 2 months. Even in cases where a normalization of PSA levels is required, no trials have factored in the definition of "normal" with regard to the presence (<4 ng/mL) or absence (0 ng/mL) of PSA or a prostate gland. PSA levels are subject to hormonal regulation. Androgen receptors bound to ligand regulate the expression of the PSA gene by binding to androgen response elements (77) . Other compounds or substances that regulate PSA expression include vitamin D, transforming growth factor-p, basic fibroblast growth factor, and protein kinase C. Agents that modulate the action of any of these compounds may modulate PSA levels independently of cell kill. Misleading short-term elevations or declines in PSA can also be observed. It is therefore important to inspect the patterns of PSA change after therapy and to include a time factor in any proposed criteria. The mechanisms of action of the drug(s) should also be considered. Fig. 1, A, shows serial declines in PSA value in a patient treated successfully with a cytotoxic approach. A steady decline in PSA level to the normal range was maintained for several months. This reduction was associated with an improvement in pain and bone scintigraphy. Fig. 1, B , illustrates a decline in PSA values between the start and finish of the chemotherapy cycles in patients treated with trimetrexate on a daily-times-five schedule (72) . This pattern was interpreted as showing a transient effect of the drug on PSA synthesis or release. A similar transient decline in a patient treated with suramin and hydrocortisone is illustrated in Fig. 1,  C (73) . The pattern is consistent with in vitro studies showing that suramin can inhibit PSA release from cells (74) . Fig. 1, D, shows the results obtained in a patient with progressive in- creases both before and after treatment with interferon and cisretinoic acid. In this case, the rise in PSA level, presumably the result of successful differentiation of the tumor, continued for 4 months, after which a decline to base line was documented. For the trial including this patient, post-therapy PSA change was not used as the end point. An additional consideration is that not all cells within a prostatic tumor will produce PSA {75). Thus, when PSA determinations are used in the clinic, it is important not to abandon other modes of tumor assessment when monitoring disease status. Although all criteria require validation in the phase III setting, we recommend for reporting purposes that the parameters of post-therapy decline be multidimensional and include the following: 1) the percentage decline, 2) the number of times the decline is documented (a minimum of three), and 3) the period during which the decline is maintained. To minimize variability, one should take care to ensure that PSA determinations are performed with the same assay and, ideally, in the same laboratory.
Acid phosphatase. Acid phosphatase levels fluctuate widely in the absence of therapy; as a result, measurements were largely abandoned when PSA testing became routine (76) . In the original report of androgen ablation as primary treatment for prostate cancer, Huggins and Hodges (77) showed a clear association between measured acid phosphatase levels and clinical response. Few groups, however, have considered quantitating the degree of decline in acid phosphatase over time. In a recent study (78) , we found discordance between declines in PSA and acid phosphatase levels in six (32%) patients who showed PSA declines. The median survival of patients showing declines in both markers exceeded that of patients showing declines in PSA alone by 1 year. This result suggested that monitoring both parameters might refine the outcomes predicted on the basis of post-therapy changes in PSA alone (78) . This hypothesis, too, will require prospective validation.
Pathologic End Points
Trials of differentiating agents or of compounds directed at a specific gene product, enzyme, or metabolic pathway may require monitoring of changes in tumor tissue to ensure that a drug has been delivered to the site of interest or that some other surrogate marker of drug activity has changed after treatment with a study agent. Sequential biopsies of a progressing primary or metastatic lesion might also be useful to define the optimal biologic dose of an agent, which is critical to the design of large-scale comparisons. Monitoring histologic and molecular changes in the prostate after treatment with a drug is a strategy that is being used with increasing frequency in patients scheduled to undergo radical surgery, which provides the entire gland for evaluation.
Subjective Criteria and Quality of Life
The inclusion of subjective criteria in many of the trials is similarly problematic, since these outcomes can be difficult to reproduce on a large scale (17, 79) . Nevertheless, from a patient's point of view, a chemotherapeutic agent that can consistently and reproducibly decrease the pain of osseous lesions with minimal toxicity would be highly beneficial. Just such results were shown in a randomized comparison of mitoxantrone with prednisone, which specifically addressed a qualityof-life objective. Although the survival distributions were similar between the two groups, a benefit was shown with respect to pain relief (with no concomitant increase in analgesic intake) for chemotherapy-treated patients. In addition, those who met the criteria for a primary response-pain reliefshowed significant post-therapy differences from base line in measures of constipation, fatigue, and physical activity (17) .
Other investigators (80) have used an index termed the "clinical benefit response," which focuses on three common clinical features of cancer patients in general: pain (measured by a visual analogue scale and analgesic consumption), performance status, and weight change. A patient is classified as either positive, negative, or stable with respect to each of the parameters, where positive indicates a sustained and significant improvement over base line. An overall positive classification assumes no "negatives" on any of the parameters. This methodology has been applied to prostate cancer patients in the clinical testing of vinorelbine tartrate (81) . Further validation is ongoing.
Outcomes: Reporting Each Measure Independently
As the criteria for "response" are evolving, it is important not to artificially box patients into specific categories such as those exhibiting a "partial response" or "stable disease," which, by virtue of the definition used by an individual investigator, limits the comparisons. We recommend that each parameter used to assess outcomes, be it a change in a marker value, a change in measurable disease, a change in bone scan findings, or a change in disease-related symptoms, be reported independently. Because of the variability in reporting the use of post-therapy marker decline, it is important not to abandon the other methods used to monitor disease activity so that concordance and discordance can be assessed. It is also important to include the duration of benefit, however defined, so that the risks are justified relative to the probability of a favorable outcome.
IV. Developmental Sequence: Knowing When to Proceed
The most serious shortcoming of a phase II trial is the failure to identify an active agent, particularly when the therapeutic options are limited (82) . There are several steps in developing a new approach.
Step I
Step I involves the identification of the appropriate patient population and the appropriate end point to evaluate a therapeutic approach based on the presumed mechanism(s) of action of the agent(s) under study. Proper dosing is critical, particularly for some of the newer compounds that do not function as cytotoxic agents, for which the optimal biologic dose is not necessarily the dose that results in a given degree of toxicity. For example, asymptomatic patients with low-volume disease may be more appropriate for a trial using an immunologic approach than symptomatic patients with bulky tumors. Similarly, post-therapy declines in PSA level might be an appropriate end point for a trial of a cytotoxic agent, but it might be inappropriate for an angiogenesis inhibitor. In some cases, changes in pathology may be the only suitable end point. For most screening trials, a cohort of 15-20 patients evaluated with posttherapy PSA changes used as the end point is required. Patterns of PSA change are also inspected. For a cytotoxic agent, both the proportion showing benefit and the duration for which the benefit is maintained will factor into the decision to continue development. If the end point of interest is satisfied in step I, an additional 15-20 patients can be enrolled to estimate the level of activity more precisely. To control for the potential contribution of a secondary endocrine effect, the trial can be designed so that entry requires progression on the modulating agent. An example is the trial conducted by Kelly et al. (34) , which restricted entry to patients whose disease progressed after anti-androgen withdrawal and hydrocortisone treatment prior to the administration of suramin. If activity is confirmed, one can proceed directly to a randomized trial with the end point of response or time to progression (step IT).
Step II Randomization gives a base-line response proportion on similar patients. In practice, we have used two-stage designs with stopping rules based on predetermined levels of activity. In such trials, if one approach has a significantly higher response proportion and the two arms are balanced with respect to known prognostic factors, the result is more likely to be correct. If both are inactive, it may represent the ineffectiveness of the test compound^) or a unique aspect of the population enrolled. Typically, however, further development ceases. A randomized design is of particular importance when attempting to determine the contribution of a hormone with known activity in relapsed disease to the outcomes observed with a chemohormonal approach. A comparison of estramustine and vinblastine versus estramustine alone is an example of such a trial.
Time to disease progression trials. The definitions of disease progression vary widely among investigators, which will have a significant impact on how the "duration of response" is reported. For example, one would expect the time to disease progression based on PSA elevations to be significantly shorter than one based on radiographic or on clinical signs. In one study (77) , no definition of disease progression was provided. The range of outcomes is shown in Fig. 2 , which is a graphical illustration of sequential PSA values from a patient who showed a greater than 80% decline in PSA from base line with systemic therapy that was documented on multiple determinations. On day 126, the PSA level began to rise. Outcomes, such as whether the patient "responded" according to biochemical criteria, the point at which the "response" is considered to have occurred, the time to the nadir value, the date of relapse, and the duration of "response," can vary considerably depending on how an investigator defines each of these variables. If, for example, one considered a 50% decline from base line as meaningful, one can see that the patient first met this "criterion" on day 28 and that the PSA level continued to decline to reach a nadir value on day 56. At that point, the PSA change would meet the criterion of three separate determinations, 2 or more weeks apart, each of which is greater than 50% from base line. What if the protocol called only for PSA determinations on an every-4-weeks basis? With the use of the same requirement for three determinations of a 50% or greater decline, the patient would not have met the criterion of response until day 84. What if the PSA value began to rise on day 56? Would the patient still be classified as a "responder" by use of the 50% decline end point? When did the patient's disease progress? Is it at the time the first rise in PSA value was documented, or the second, or the third? When is one convinced that an elevation is "real" and not simply a laboratory artifact?
From the perspective of the patient, the most important outcome is how long the "benefit" lasts. The duration of benefit will clearly have an impact on the decision to recommend treatment, the patient's acceptance of that treatment, and the decision to continue development of that approach. The end point of "progression" is distinct from "time to treatment failure," which includes patients whose disease has progressed while on treatment as well as those who are removed from study because of adverse events (83, 84) . Such an approach may be particularly useful for a drug that does not function as a classical cytotoxic agent and where "response" may be difficult to assess. Trials of differentiating agents, antimetastatic compounds, or an- Graphical illustration of sequential prostate-specific antigen (PSA) values from a theoretical patient treated with systemic therapy who showed a greater than 80% decline in PSA from base line that was documented on multiple determinations. Later, a rise in PSA value was noted. Arrows highlight the points that could be used to determine specific intervals. These include the time at which A) the response is first documented (day 28), and B) patient is considered to have had a relapse (day 126). Other intervals that could be calculated would include the "duration of response" and the "time to progression." giogenesis inhibitors may be particularly amenable to this type of approach. However, when this approach is utilized, care must be taken to ensure that 1) an adequate number of patients are enrolled, 2) the criteria for disease progression are well defined and reproducible, and 3) patients are re-evaluated with all parameters of disease at fixed time intervals. For continued development of a particular approach, a minimum time to disease progression of 6 months or more is suggested. Survival. A phase III trial is the setting in which any proposed criterion can be validated prospectively and the true benefit of an approach can be assessed. The recommended approach is a comparison of the experimental treatment with a "standard" therapy or best supportive care. Sample size considerations and the comparative morbidity of the experimental treatments must also be considered when designing such trials. Low-dose prednisone has been used as the "control" arm in several such studies based on the palliative effects observed in a phase II trial (85) . The critical issue is what level of efficacy in the phase II setting would an investigators) think is sufficient to address a phase III question using a survival end point. These trials are large and costly. Most phase II trials involving patients who have had disease progression while on hormone therapy report a median survival of approximately 10 months (23, 48) . Recognizing the potential impact of lead-time bias on reported survival from single-arm phase II investigations, a drug or approach that doubles this median might be considered for further study.
To influence clinical practice and change "standards of care" for a particular disease, a treatment program should be tested in a randomized phase III trial using the end point of survival. No phase III trial in patients with relapsed prostate cancer has shown a survival benefit for the experimental versus the control arm. Most likely, this outcome is because our currently available treatments are not effective; however, many trials were simply too small to exclude a small difference even if one existed. The National Prostatic Cancer Project was one of the first groups to conduct randomized trials comparing single agents with best supportive care (86) . This group reported an increase in the mean survival time for cyclophosphamide versus the "standard" therapy; however, no improvement in median survival was shown upon reanalysis. Based on the sample size evaluated in each treatment group, however, a 70%-80% improvement in median survival would have been required in the experimental group relative to the control group for differences to be significant (48) .
Physician and patient acceptance of randomization is also a critical consideration when designing such trials (87) . For example, a clinical trial of suramin and hydrocortisone versus hydrocortisone alone, designed shortly after promising results were observed in an early National Cancer Institute trial (88), accrued fewer than 10 patients in 14 months. The question remains unresolved. Based on currently available therapies, a definitive 25% increment in survival might be considered significant, a more conservative estimate than that utilized by the National Prostatic Cancer Project investigators (89, 90) . However, because such a trial would be large and costly, a sequential trial design is advised because it provides the opportunity to end a trial if one approach is clearly inferior. Independent auditors are recommended to make appropriate adjustments as the trial is ongoing. The "intent-to-treat" principle is also recommended for the analysis if patients cross over from one arm to the other. If a new prognostic factor arises in the interim that is not adjusted for in the randomization, this factor can be assessed in the final analysis to ensure that the treatment difference is real and not an artifact of this new factor.
Summary: Let Us All Speak the Same Language
Reporting the results of a clinical trial requires a clear statement of the hypothesis of the study, the study design, and the statistical measures proposed to determine a clinically meaningful outcome. The eligible patient population should also be clearly defined, both with respect to disease extent and hormone sensitivity. With the exception of the generally accepted criteria for measurable disease regression, the other parameters used to assess outcomes in patients with prostatic cancer have not been standardized or validated through associations with changes in measurable disease or in relation to survival in phase III trials using a survival end point.
Use of different definitions of a "meaningful" decline in PSA value and forcing patients into an "overall response category" result in marked variations in outcomes with the same agents. The issues of standardization of enrollment criteria, methods of evaluation, and reporting of response are essential so that we can develop effective therapies based on reliable clinical trial data and discard, rapidly and definitively, inactive compounds from future development. We believe strongly that, rather than force patient outcomes into a single "category" such as a partial response or stable disease, a better approach would be for all investigators to record outcomes based on each disease-related parameter independently. In this fashion, as the specific criteria used to categorize outcomes are validated in large, randomized trials using the end point of survival, we will be in a better position to compare results and to classify patient outcomes accurately and consistently. This situation will ultimately serve to expedite drug development through the rapid rejection of inactive therapies and the early design of the requisite comparative trials to assess the true role of a given treatment in the phase III setting. Finally, there remains an urgent need to re-evaluate the traditional cytotoxic drugs in specific patient populations where the heterogeneity of entry criteria and patient demographics are minimized. Until such time as the "true" response proportion to a particular agent is described, many patients will receive inactive treatments or be denied active therapies for their cancers. Increasing the homogeneity of the population enrolled in a trial will result in more rapid, more reproducible, and, ultimately, less costly testing of a therapeutic approach.
